Research Paper Volume 13, Issue 9 pp 12865—12895

Integrative analysis identifies key mRNA biomarkers for diagnosis, prognosis, and therapeutic targets of HCV-associated hepatocellular carcinoma

Performance of the defined four mRNA-based risk signature with ICGC-LIRI-JP. (A) Gene expression, risk score, and clinical outcome for all the patients in distinctive risk groups. (B) differential risk scores between high- and low-risk groups. (C) ROC plot at 3 years OS showing the AUROC score of 0.778. (D) OS Kaplan-Meier survival curves for high- and low-risk patients. (E, F) OS Kaplan-Meier survival curves for different risk groups of early stage (E) and advanced stage patients (F). ****, P

Figure 9. Performance of the defined four mRNA-based risk signature with ICGC-LIRI-JP. (A) Gene expression, risk score, and clinical outcome for all the patients in distinctive risk groups. (B) differential risk scores between high- and low-risk groups. (C) ROC plot at 3 years OS showing the AUROC score of 0.778. (D) OS Kaplan-Meier survival curves for high- and low-risk patients. (E, F) OS Kaplan-Meier survival curves for different risk groups of early stage (E) and advanced stage patients (F). ****, P < 0.0001. OS, overall survival. ROC, receiver operating characteristic. AUROC, the area under the receiver operating characteristic curve.